Baxter International Inc (N:BAX)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | DF2-1W, ONE BAXTER PKWY DEERFIELD IL 60015 |
| Tel: | 1-224-9483020 |
| Website: | https://www.baxter.com |
| IR: | See website |
| Key People | ||
| Jose E. Almeida Chairman of the Board, President, Chief Executive Officer | Brian Stevens Senior Vice President, Chief Accounting Officer, Controller | Joel T. Grade Chief Financial Officer, Executive Vice President |
| Jeanne K. Mason Chief Human Resource Officer, Executive Vice President | David S. Rosenbloom Executive Vice President, General Counsel | James W. Borzi Executive Vice President and Chief Supply Chain Officer |
| Heather Knight Executive Vice President, Group President - Medical Products and Therapies | Reaz Rasul Executive Vice President, Group President - Healthcare Systems and Technologies | Alok Sonig Executive Vice President, Group President - Pharmaceuticals | Christopher A. Toth Executive Vice President and Group President, Kidney Care |
| Business Overview |
| Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company's Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies and precision positioning devices. Its Pharmaceuticals segment includes specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Its Kidney Care segment includes chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, Baxter International Inc revenues increased 2% to $14.81B. Net loss before extraordinary items decreased 97% to $76M. Revenues reflect Medical Products and Therapies segment increase of 4% to $5.01B, Pharmaceuticals segment increase of 6% to $2.25B, Healthcare Systems and Technologies segment increase of 3% to $3.01B, United States segment increase of 10% to $7.64B. |
| Employees: | 60,000 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $30,708M as of Dec 31, 2023 |
| Annual revenue (TTM): | $14,813M as of Dec 31, 2023 |
| EBITDA (TTM): | $2,858M as of Dec 31, 2023 |
| Net annual income (TTM): | -$76.00M as of Dec 31, 2023 |
| Free cash flow (TTM): | $448.00M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $10,604M as of Dec 31, 2023 |
| Shares outstanding: | 509,347,000 as of Mar 14, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.